Ivonescimab Demonstrates Statistically Significant Overall Survival Advantage Over Pembrolizumab in HARMONi-2
SMMT sits 27% above its 52-week low of $12.07.
Summary
Akeso's HARMONi-2 trial showed ivonescimab monotherapy beat pembrolizumab on overall survival in PD-L1-positive NSCLC — the first OS data from this study, reinforcing the drug's clinical profile ahead of the November PDUFA decision.
Key Events · Product Development and Regulatory · SMMT
-
HARMONi-2 OS Benefit
Ivonescimab monotherapy demonstrated a statistically significant overall survival improvement vs pembrolizumab monotherapy in PD-L1-positive advanced NSCLC (preplanned secondary endpoint analysis).
-
Fifth Positive Phase III Readout
This marks the fifth positive Phase III ivonescimab readout to date — four in NSCLC and one in biliary tract cancer — all with positive data.
-
China-Only Data
HARMONi-2 is a single-region study conducted in China and sponsored by Akeso; ivonescimab remains investigational and unapproved in Summit's license territories, including the US and Europe.
-
PDUFA Date November 14, 2026
The FDA accepted Summit's BLA for ivonescimab in EGFR-mutated NSCLC (HARMONi) with a goal PDUFA date of November 14, 2026.
Analysis · SMMT · Life Sciences
Akeso, Summit's partner, reported that ivonescimab monotherapy achieved a statistically significant overall survival improvement over pembrolizumab monotherapy in the Phase III HARMONi-2 study in PD-L1-positive advanced NSCLC. This first OS readout from the trial adds to a growing body of positive survival data across five Phase III readouts. The result strengthens the case for ivonescimab's differentiated profile ahead of the November 14, 2026 PDUFA date for the HARMONi BLA, though the data are from a China-only study and the drug remains unapproved in Summit's territories.
How filings like this one have moved
In the 30 days to Sep 9, 2026, 36.4% of the 1919 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SMMT was trading at $15.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.6B. The 52-week trading range was $12.07 to $29.23. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.